Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Eschmann

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2006
Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivorsS M Eschmann, G Friedel, F Paulsen, et al.
The British Journal of Radiology|March 3, 2007
Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imagingA C Pfannenberg, P Aschoff, K Brechtel, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2006
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancerS M Eschmann, G Friedel, F Paulsen, et al.
Der Radiologe|September 25, 2007
[Cost considerations for whole-body MRI and PET/CT as part of oncologic staging]C Plathow, M Walz, M P Lichy, et al.
Nuklearmedizin. Nuclear Medicine|June 2, 2010
Lesion concordance, image quality and artefacts in PET/CT: results of a multicenter studyH Stergar, B J Krause, S M Eschmann, et al.
Nuklearmedizin. Nuclear Medicine|October 17, 2007
Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancerS M Eschmann, A C Pfannenberg, A Rieger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 5, 2005
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?S M Eschmann, G Friedel, F Paulsen, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2006
Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivorsS M Eschmann, G Friedel, F Paulsen, et al.
The British Journal of Radiology|March 3, 2007
Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imagingA C Pfannenberg, P Aschoff, K Brechtel, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2006
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancerS M Eschmann, G Friedel, F Paulsen, et al.
Der Radiologe|September 25, 2007
[Cost considerations for whole-body MRI and PET/CT as part of oncologic staging]C Plathow, M Walz, M P Lichy, et al.
Nuklearmedizin. Nuclear Medicine|June 2, 2010
Lesion concordance, image quality and artefacts in PET/CT: results of a multicenter studyH Stergar, B J Krause, S M Eschmann, et al.
Nuklearmedizin. Nuclear Medicine|October 17, 2007
Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancerS M Eschmann, A C Pfannenberg, A Rieger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 5, 2005
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?S M Eschmann, G Friedel, F Paulsen, et al.
Pageof 2